Abstract | BACKGROUND: PATIENTS: Patients with synchronous clinical stage III melanoma were identified from the OpACIN, OpACIN-neo and PRADO neoadjuvant trials, where all patients were treated with ipilimumab plus nivolumab. An additional case treated outside those clinical trials was included. RESULTS: Seven patients were identified; six patients had a concordant response in primary site melanoma lesions or in-transit metastasis and the lymph node metastases. One patient had concordant progression in both the primary and nodal tumour lesions and developed stage IV disease during neoadjuvant treatment, and thus, no resection was performed. CONCLUSION:
|
Authors | Judith M Versluis, Irene L M Reijers, Elisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, Michel W Wouters, Sydney Ch'ng, Robyn P M Saw, Richard A Scolyer, Bart A van de Wiel, Bastian Schilling, Georgina V Long, Christian U Blank |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 148
Pg. 51-57
(05 2021)
ISSN: 1879-0852 [Electronic] England |
PMID | 33735809
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Ipilimumab
(administration & dosage)
- Male
- Melanoma
(drug therapy, pathology)
- Middle Aged
- Neoadjuvant Therapy
(mortality)
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Neoplasm Staging
- Neoplasms, Multiple Primary
(drug therapy, pathology)
- Nivolumab
(administration & dosage)
- Retrospective Studies
- Survival Rate
|